GLAXO quarterly results and annual financials: sales, operating profit, OPM, net profit, EPS, balance sheet, cash flow and ratios like ROCE, with YoY and QoQ growth.
GlaxoSmithKline Pharmaceuticals Ltd reported sales of ₹1,184 Cr, operating profit of ₹402 Cr (OPM 34%) and net profit of ₹336 Cr for the quarter ended Sep 2026. Figures in ₹ crore, consolidated where available.
GLAXO quarterly results (₹ Cr)
Metric
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Sales
949
974
805
980
1,041
995
938
1,184
YoY Sales growth
18
5
-1
-3
10
2
17
21
Expenses
658
641
554
644
670
644
643
782
Operating Profit
292
333
251
336
371
351
296
402
OPM
31%
34%
31%
34%
36%
35%
31%
34%
Other Income
35
41
44
36
50
36
44
73
Interest
0
1
0
1
1
1
1
0
Depreciation
19
15
16
17
20
13
16
15
Profit before tax
308
359
279
354
400
373
322
459
Tax
25%
27%
27%
27%
26%
26%
26%
27%
Net Profit
230
263
205
257
296
278
237
336
EPS in Rs
13.57
15.52
12.1
15.2
17.45
16.4
14
19.83
GLAXO profit & loss, annual (₹ Cr)
Metric
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
TTM
Sales
3,278
3,252
3,454
3,749
3,822
4,159
Sales growth
12
-1
6
9
2
12
Expenses
2,516
2,447
2,545
2,570
2,512
2,739
Operating Profit
762
804
909
1,179
1,309
1,420
OPM
23%
25%
26%
31%
34%
34%
Other Income
1,401
103
-21
149
166
203
Interest
2
2
2
1
3
3
Depreciation
68
66
70
67
66
64
Profit before tax
2,093
839
816
1,260
1,406
1,555
Tax
19%
27%
28%
26%
26%
-
Net Profit
1,695
611
590
928
1,036
1,147
EPS in Rs
100.04
36.05
34.83
54.75
61.15
67.68
Dividend Payout
90%
89%
92%
99%
93%
-
GLAXO balance sheet (₹ Cr)
Metric
Mar 2024
Mar 2025
Sep 2025
Mar 2026
Sep 2026
Equity Capital
169
169
169
169
169
Reserves
1,608
1,782
1,538
2,098
1,712
Borrowings
19
10
36
33
39
Other Liabilities
1,760
2,147
1,922
2,023
2,048
Total Liabilities
3,557
4,108
3,665
4,324
3,969
Fixed Assets
321
284
291
281
293
CWIP
14
14
17
33
35
Investments
813
1,118
1,313
1,392
1,525
Other Assets
2,408
2,692
2,044
2,618
2,116
Total Assets
3,557
4,108
3,665
4,324
3,969
GLAXO cash flows (₹ Cr)
Metric
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Cash from Operating Activity
811
484
582
1,290
903
Cash from Investing Activity
-406
808
9
-46
397
Cash from Financing Activity
-524
-1,543
-562
-769
-737
Net Cash Flow
-119
-251
29
475
563
Free Cash Flow
2,371
451
573
1,273
870
CFO/OP
122%
93%
92%
116%
93%
CFO/EBITDAShare of operating profit converting into cash: CFO (before tax) / Operating Profit